Shareholder Update

Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on neurodevelopmental disorders, today announces an interim update to its shareholders on significant progress during the past three months.

On 18 February 2009 the Company announced the top-line results for the SOFIA study in Autistic Disorder of NPL-2008, a novel formulation of fluoxetine, which showed that this study had not met its primary endpoint of demonstrating a statistically significant difference between NPL-2008 and placebo treatment.

The Company has largely completed the analysis of the results from this study and is now in discussion with clinicians and experts in the field, who continue to express strong support for the product. In addition, following considerable interest in NPL-2008 from a number of parties, discussions have progressed well with a third party pharmaceutical company for a potential collaboration which would encompass the further development and commercialisation of NPL-2008. Neuropharm is therefore developing study designs for a second Phase III study, in conjunction with the partner.

Neuropharm’s intention would be to conduct a further Phase III study for NPL-2008 with a modified trial design, incorporating the important findings and insights from SOFIA, which will be funded through the collaboration. It is expected that a deal will be signed by the autumn of this year.

For further information please contact:

Neuropharm +44 (0) 1372 371 171

Robert Mansfield, Chief Executive Officer

Graham Yeatman, Chief Financial Officer

Piper Jaffray Ltd. +44 (0) 20 3142 8700

Neil Mackison, Rupert Winckler

Buchanan Communications +44 (0) 20 7466 5000

Mark Court, Mary-Jane Johnson, Catherine Breen

Notes to Editors:

About Neuropharm

Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.ukfor further information.